Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Avutometinib |
RAF/MEK Clamp | Solid Tumour | ||
|
Molecule
Avutometinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RAF/MEK Clamp |
||||
Axitinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Axitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Balstilimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Balstilimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Bavdegalutamide |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
Bavdegalutamide
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
Belantamab Mafodotin |
ADC | Hematologic | ||
|
Molecule
Belantamab Mafodotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Belinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Belinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Belzutifan |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Belzutifan
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Bempegaldesleukin |
Interferon / Interleukin | Both (Solid & Hematologic) | ||
|
Molecule
Bempegaldesleukin
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Interferon / Interleukin |
||||
Berzosertib |
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) | Solid Tumour | ||
|
Molecule
Berzosertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
||||
Bevacizumab |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Bevacizumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Binimetinib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Binimetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Bleximenib |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Bleximenib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
AvutometinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RAF/MEK Clamp |
|
AxitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
BalstilimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
BavdegalutamideTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|
Belantamab MafodotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
BelinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
BelzutifanTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
BempegaldesleukinImmunotherapy (Cytokine) |
|
|
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Interferon / Interleukin |
|
BerzosertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
|
BevacizumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
BinimetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
BleximenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|